MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer

Molecular Cancer Research

Volumn 10, Issue 2, 2012, Pages 259-269

  Ikeda, Yushi ^a,b   Tanji, Etsuko ^a   Makino, Naohiko ^b   Kawata, Sumio ^b   Furukawa, Toru ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 181D; MICRORNA 193B; MICRORNA 34A; MICRORNA 7-3; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CCND1 GENE; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; NT5E GENE; PANCREAS CANCER; PHENOTYPE; PLAU GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STARD7 GENE; STMN1 GENE; UPREGULATION; YWHAZ GENE;

BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84857204305     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0035     Document Type: Article

References (42)

1. Kato H, Sobue T, Katanoda K, Saito Y, Tsukuma H, Sakura N, et al., editors. Cancer statistics in Japan. Tokyo: National Cancer Center; 2008.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-83. (Pubitemid 47321600)
4. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-Kras genes. Cell 1988;53:549-54.
5. Thatcher JD. The Ras-MAPK signal transduction pathway. Sci Signal 2010;3:tr1.
6. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003;163:1255-60. (Pubitemid 37175075)
7. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162:1807-15. (Pubitemid 36613039)
8. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006;25:4831-9. (Pubitemid 44201174)
9. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-8. (Pubitemid 33032103)
10. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-40.
11. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009;174:1131-8.
12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. (Pubitemid 40839735)
13. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61. (Pubitemid 43271657)
14. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-8. (Pubitemid 46707844)
15. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442-52. (Pubitemid 47014466)
16. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004. (Pubitemid 38327724)
17. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-52. (Pubitemid 46856245)
18. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20. (Pubitemid 40094598)
19. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007;27:91-105. (Pubitemid 46991392)
20. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
21. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009;284:5731-41.
22. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4. (Pubitemid 47014436)
23. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007;26:5017-22. (Pubitemid 47172643)
24. Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 2001;8:89-92. (Pubitemid 33758206)
25. Hata T, Ogawa T, Yokoyama TA, Fukushige S, Horii A, Furukawa T. DSCP1, a novel TP53-inducible gene, is upregulated by strong genotoxic stresses and its overexpression inhibits tumor cell growth in vitro. Int J Oncol 2004;24:513-20.
26. Whittaker R, Loy PA, Sisman E, Suyama E, Aza-Blanc P, Ingermanson RS, et al. Identification of microRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening. J Biomol Screen 2010;15:798-805.
27. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009;28:3937-48.
28. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, Garady C, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010;176:2520-9.
29. Strater N. Ecto-5′-nucleotidase: Structure function relationships. Purinergic Signal 2006;2:343-50.
30. Spychala J. Tumor-promoting functions of adenosine. Pharmacol Ther 2000;87:161-73.
31. Angeletti S, Maggio B, Genti-Raimondi S. Surface activity and interaction of StarD7 with phospholipid monolayers. Biochem Biophys Res Commun 2004;314:181-5. (Pubitemid 38058386)
32. Durand S, Angeletti S, Genti-Raimondi S. GTT1/StarD7, a novel phosphatidylcholine transfer protein-like highly expressed in gestational trophoblastic tumour: cloning and characterization. Placenta 2004;25:37-44. (Pubitemid 38100764)
33. Lee HS, Park MH, Yang SJ, Park KC, Kim NS, Kim YS, et al. Novel candidate targets of Wnt/beta-catenin signaling in hepatoma cells. Life Sci 2007;80:690-8. (Pubitemid 46074058)
34. Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R, et al. Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 1998;78:701-9. (Pubitemid 28418300)
35. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, et al. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 2008;19:2003-13.
36. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007;46:759-68. (Pubitemid 47436122)
37. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003;2:107-16.
38. Marklund U, Brattsand G, Shingler V, Gullberg M. Serine 25 of oncoprotein 18 is a major cytosolic target for the mitogen-activated protein kinase. J Biol Chem 1993;268:15039-47.
39. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010;16:214-8.
40. Lin M, Morrison CD, Jones S, Mohamed N, Bacher J, Plass C. Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J Cancer 2009;125:603-11.
41. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
42. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A 2007;104:17719-24. (Pubitemid 350210901)